Idorsia Ltd
🇨🇭Switzerland
A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and Midazolam
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03017495
- Locations
- 🇩🇪
Investigator Site, Kiel, Germany
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lucerastat (CDP923) After Multiple Dosing in Healthy Subjects
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT02944474
- Locations
- 🇬🇧
Investigator Site, Edinburgh, United Kingdom
A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy Subjects
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT02944487
- Locations
- 🇬🇧
Investigator Site, Tranent, United Kingdom
A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease
Phase 1
Completed
- Conditions
- Fabry Disease
- Interventions
- Drug: Enzyme replacement therapy (ERT)
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT02930655
- Locations
- 🇩🇪
Investigator Site, Würzburg, Germany
A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: Placebo (Formulation A)Drug: Placebo (Formulation B)Drug: Placebo tracer
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02919319
- Locations
- 🇳🇱
Investigator Site, Leiden, Netherlands
A Study to Evaluate Cenerimod in Healthy Male Subjects
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT02914223
- Locations
- 🇳🇱
PRA Health Science, Groningen, Netherlands
A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT02905253
- Locations
- 🇬🇧
Covance Clinical Research Unit, Leeds, United Kingdom
Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT02841709
- Locations
- 🇩🇪
Investigator Site, Schwerin, Germany
A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02841761
- Locations
- 🇺🇸
Investigator Site, Newark, New Jersey, United States
Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder
Phase 2
Completed
- Conditions
- Insomnia Disorder
- Interventions
- Drug: Placebo 1Drug: Placebo 2
- First Posted Date
- 2016-07-20
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT02839200
- Locations
- 🇸🇪
Investigator Site, Örebro, Sweden
© Copyright 2025. All Rights Reserved by MedPath